Overview

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Status:
Unknown status

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

This randomised, controlled, open-label, prospective trial is designed to assess the efficacy and safety of icotinib maintenance therapy after sequential Icotinib plus chemotherapy versus Icotinib maintenance therapy after chemotherapy in stage IIIB/IV non-small cell lung cancer patients with EGFR mutation.

Phase:

Phase 4

Details

Lead Sponsor:

Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.

Treatments:

Cisplatin
Gemcitabine